Embed Size (px)
Citation preview
eng.sheba.co.il Center Sheba Medical
Sheba International sheba-international.sheba.co.il
Medical Research and Development rnd.sheba.co.il
Director General, Sheba Medical Hashomer-Center, Tel
2
Professor Yitshak Kreiss is the Director General of the Sheba Medical Center, Tel Hashomer. For the last three decades, Professor Kreiss served in the Israel Defense Forces where he ascended from serving as a front line combat surgeon, through all levels of command, until assuming overall leadership of the Medical Corps as the Surgeon General. Professor Kreiss has treated victims in conflicts and wars and in numerous emergency and disaster situations all over the world. He is a Professor of Medicine at Tel Aviv University, and Associate Professor at the Hebrew University Faculty of Medicine and a visiting professor at Florida Atlantic University. Professor Kreiss' research in health management in times of emergency is based on the humanitarian operations he led and focuses on: health management of field hospitals; leadership and ethics in times of emergency; and medical care for disaster challenges. His research has contributed significantly to the development of current concepts and approaches and is widely acknowledged as one of the most insightful publications on the subject of medical relief in natural disasters.
As we approach the 70th anniversary of the Sheba Medical Center (SMC) , Tel Hashomer, Israel, I am very proud to present our guide to Bio-Medical Opportunities at the SMC. The Sheba Medical Center, Israel's largest hospital has made a commitment to clinical excellence, based on a strong research and development foundation, by investing in professional human resources, infrastructure and facilities. Sheba provides its staff with a working environment that stimulates research and innovation for the benefit of patients. Known for our groundbreaking medical research, the Sheba Medical Center is home to major specialized research centers, integrating basic research, translational research and clinical studies across a broad spectrum of medical disciplines. SMC scientists and doctors, together with industry, co-develop breakthrough medical innovations, including therapeutic solutions, diagnostic tools, imaging modalities, drug delivery systems and medical devices. Our internationally renowned scientists have made significant contributions to the advancement of knowledge and medical solutions in fields as diverse as cell biology, biotechnology, genetics, imaging, and medical technologies. I invite you to peruse this guide, to identify opportunities for collaboration and partnerships with our physicians and scientists and to join us in helping to improve the lives of people in our region and around the globe.
Professor Yitshak Kreiss, MD, MHA, MPH Director General, Sheba Medical Center, Tel-Hashomer
In order to assist you in identifying areas of interest and potential collaboration, the research institutes in this guide have been categorized into 4 groups reflecting the prime research directions: Translational research, Medical technologies, Basic science research and Clinical research.
The Index page and pages for each institute are labeled with the appropriate symbol/s:
The Chaim Sheba Medical Center 3
CANCER RESEARCH CENTER & WOHL INSTITUTE FOR TRANSLATION MEDICINE_____________________________ ONCOLOGY___________________________________________ HEMATOLOGY ________________________________________ THE BREAST CANCER TRANSLATIONAL RESEARCH LABORATORY_________________________________________ THE ELLA LEMELBAUM INSTITUTE FOR IMMUNO-ONCOLOGY___________________________________________ CANCER EPIGENETIC LABORATORY __________________ BRAIN TUMORS, NOVEL TREATMENTS AND MR IMAGING METHODS _________________________________ RADIATION ONCOLOGY ______________________________ THE USE OF CPAP TO REDUCE TUMOR MOTION ______ PATHOLOGY __________________________________________ INFECTIOUS DISEASES UNIT THE MOLECULAR LIVER RESEARCH LABORATORY THE CENTER OF LIVER DISEASES IBD SERVICE & GASTRO-IMMUNOLOGY ______________ ENDOCRINE RESEARCH UNIT_________________________ NEUROLOGY__________________________________________ NEUROLOGY, MULTIPLE SCLEROSIS __________________
6
10 11
12
14 16
17 20 21 22 25
26 28 29 30 32
4 The Chaim Sheba Medical Center
NEUROSCIENCE, ADVANCED TECHNOLOGIES IN REHABILITATION __________________________________ NEUROLOGICAL REHABILITATION ___________________ OPHTHALMOLOGY ___________________________________ STEM CELLS & REGENERATIVE MEDICINE_____________ THE RESEARCH CENTER OF LEUKEMIA AND CHILDHOOD MALIGNANCIES________________________ PEDIATRIC HEMATO-ONCOLOGY_____________________ PEDIATRIC IMMUNOLOGY___________________________ PEDIATRIC INTENSIVE CARE _________________________ CARDIOVASCULAR ___________________________________ CARDIOLOGY ________________________________________ INTERVENTIONAL & CLINICAL CARDIOLOGY ________ INTERVENTIONAL CARDIOLOGY _____________________ PACING & ELECTROPHYSIOLOGY _____________________ CARDIAC REHABILITATION AND PREVENTION _______ LIPID METABOLISM, ATHEROSCLEROSIS _____________ HEART TRANSPLANTATION AND MECHANICAL CIRCULATORY SUPPORT ______________________________ ATHEROSCLEROSIS___________________________________
33 34 35 36
37 38 39 40 41 42 43 44 45 46 47
48 49
5 The Chaim Sheba Medical Center
Our research projects include:
• The deciphering of the role of RNA epigenetics, including RNA editing and RNA methylation in the regulation of gene expression and cell fate.
• The study of transposable genetic elements in cancer and development
• Genetically non-identical tumors • Genetic and genomic studies
relevant to cancer and genetic diseases
Director, Sheba Cancer Research Center Prof Gidi Rechavi is the founder and Director of the Sheba Cancer Research Center. He is Professor of Hematology at the Sackler Faculty of Medicine and holds the Djerassi Chair in Oncology, Tel Aviv University. He is board certified in Hematology, Pediatrics, and Pediatric Hematology-Oncology. Prof Rechavi is a member of the European Academy of Cancer Sciences and the Israel Academy of Sciences. His main research interests are RNA epigenetics, transposable genetic elements and cancer genomics with special emphasis on pediatric cancer. He has been awarded numerous prizes including the Kennedy award, the Stein award, the Seroussi Memorial Cancer Research award, the Prize for Vision in Medicine and the Elkales Prize for Distinctive Scientist in Medicine. In 2013 Prof Rechavi received the EMET prize for Genetics and he was selected for the Beutler Research Program of Excellence in Genomic Medicine. Prof Rechavi has published more than 465 articles in prestigious journals including Nature, Science, Nature Genetics, Nature Medicine, Nature Cell Biology, Nature Biotechnology, Nature Structural and Molecular Biology, Cell Stem Cell, New England Journal of Medicine and the Lancet.
www.gidirechavilab.com [email protected]
The Chaim Sheba Medical Center 6 IndexBack to
SELECTED PUBLICATIONS Frye M, Jaffrey SR, Pan T, Rechavi G, Suzuki T (2016) RNA modifications: what have we learned and where are we headed? Nat Rev Genet. 2016 Jun;17(6):365-72 Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S et al, "The dynamic N1-methyladenosine methylome in eukaryotic messenger RNA" Nature, 2016 Feb 25;530(7591):441-6 Choi J, Ieong K et al "N6-methyladenosine in mRNA disrupts tRNA selection and translation-elongation dynamics" Nature Structural & Molecular Biology, 2016 Feb ; 23(2):110-5. Geula S, Moshitch-Moshkovitz S, Dominissini D et al. 2015. "m6A mRNA methylation facilitates resolution of naïve pluripotency toward differentiation." Science 2015 Feb 27;347(6225):1002-6 Dominissini D Roadmap to the epitranscriptome Science 5 December 2014: Vol. 346 no. 6214 p. 1192 Fu Y, Dominissini D, Rechavi G, He C. Gene expression regulation mediated through reversible m6A RNA methylation. Nature Reviews Genetics 2014 May;15(5):293-306 Vilboux T, Lev A, Malicdan MC et al A Congenital Neutrophil Defect Syndrome Associated with Mutations in Vps45 New England Journal of Medicine 2013 Jul 4;369(1):54-65 Dominissini D, Moshitch-Moshkovitz S, Schwartz S et al Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq Nature 2012 May 10, 485 201-206
The Chaim Sheba Medical Center 7 IndexBack to
“After years in the dark, we were instantly facing a
wide vista,” wrote Dan Dominissini, an author of
one of the studies, in an essay in Science.
The Chaim Sheba Medical Center 8
The Chaim Sheba Medical Center 9
Director, Oncology Institute Dr. Raanan Berger is the Director of the Oncology Institute at the Sheba Medical Center, and a senior physician at the Oncology Institute treating tumors in the urogenital system. He is also secretary of the Israeli Society of Clinical Oncology and Radiotherapy. His MD and PhD degrees are from Tel Aviv University and he was a postdoctoral fellow at the Dana Farber Cancer Institute at Harvard Medical School. In 2007, he established the Riva Koschitzky Oncology Clinical Research Center at Sheba, which is the largest center for all-phase oncology clinical trials in Israel. Today he is in charge of all clinical research activity at the institute. Dr. Berger led his institute to become one of the most active partners in the Worldwide Initiative Networking (WIN) Consortium and he is the PI of the WINTHER-1 trial for personalized cancer medicine.
The Riva Koschitzky Oncology Clinical Research Unit: • We are a center of excellence within the Oncology Institute at the
Sheba Medical Center. The unit oversees all aspects of trial operations within the Oncology Institute, from contracting to endpoint analysis, including monitoring and auditing.
• We have established an international reputation as a dependable major recruiter of patients for pivotal studies.
• The unit of clinical research is divided into two sections: early phase (I/II) and late phase; both are highly specialized in conducting academic or industry sponsored trials to the highest scientific and ethical standards.
• We are conducting over 200 clinical trials in all phases • We conduct translational research in collaboration with the Sheba
Cancer Research Center, supervised by Prof. Gidi Rechavi • We have a special program for personalized cancer medicine and
basic research, aiming to undercover novel mechanisms in breast cancer, pancreatic cancer and lung cancer etc.
The Chaim Sheba Medical Center 10 IndexBack to
Director of the Division of Hematology and Director of Bone Marrow Transplantation and Cord Blood Bank Prof Nagler is Professor of Medicine at the Sackler Faculty of Medicine, Tel-Aviv University and Visiting Professor Pierre and Marie Curie University, Paris, France. He established the first public cord blood bank and performed the first cord blood transplantation in Israel Prof. Nagler is Chairman of the Acute Leukemia Working Party (ALWP) of the European Society for blood and marrow transplantation and Co-Chairman of the Scientific Council of the EBMT He served as Leader of the Alternative Donor Subcommittee of the ALWP of the EBMT from 2008-2010 and has served as Leader of the RIC subcommittee of the ALWP of the EBMT – since 2010 Member of multiple national and international societies and committees Serves on the Editorial Board of several BMT and Hematology Journals and is a section Editor for Leukemia
• Prof. Arnon Nagler has been working in the field of bone marrow transplantation for hematological malignancies, for the last 25 years. He is one of the pioneers of the non myeloablative and reduced intensity/toxicity allogeneic transplantations for both malignant and non-malignant disorders. His main contributions and scientific interests include hematopoietic stem cell transplantation, hematological malignancies, cord blood biology and transplantation and adoptive cell-mediated immunotherapy including NK cell biology.
• Prof Nagler has written numerous original articles, reviews and chapters for top rank peer-review journals including JCO, Blood, JEM, JI, EJI ,Leukemia and many others and is the principal investigator for multiple clinical studies including first to human trials with novel molecules like Pidilizumab (McAb against PD-1) and BL8040 (novel CXCR4 antagonist). Prof. Nagler is the inventor of multiple patents including for purging of BM with NK cells and the inhibition of fibrosis by Halofuginon.
• Prof. Nagler has received several awards including the best scientific abstract award of the ASBMT/CIBMR Tandem meeting (2004) and the best clinical abstract award of the NMDP Council Meeting (2004). In addition, Dr Nagler is a popular speaker and has made numerous, invited, international presentations and many oral presentations on an almost annual basis in all international transplantation and hematology meetings - ASH,ASBMT/CIBMTR, EBMT, EHA, Exp Hematology (including a presentation at the presidential symposium) and invited presentation at the Gordon conference (Boston USA).
The Chaim Sheba Medical Center 11 IndexBack to
The Breast Cancer Translational Research Laboratory has established and pursues a close collaboration between basic research scientists, oncologists, radiologists and pathologists, all committed to conduct advanced research in the field of breast cancer. The Breast Cancer Institute conducts many collaborations with scientists and bioinformaticians from Israel and from worldwide leading academic and medical institutes.
Director of the Breast Oncology Institute in Sheba Medical Center. President of the Oncology Institute in Sheba Medical Center. Prof. Kaufman is Professor of Medicine at the Sackler Faculty of Medicine, Tel Aviv University. She has supervised many clinical trials, as well as, translational studies in the field of breast cancer. She is a member of national cancer research committees, as well as, a member in international scientific advisory boards for breast cancer (prIME Oncology, Susan G. Komen Foundation). Bella Kaufman is the head of a Translational Breast Cancer Research Group aiming to integrate basic research in the field of breast cancer with clinical investigation. [email protected]
The Chaim Sheba Medical Center 12 IndexBack to
Our research focuses on: • Tumor Evolution:
• Molecular and Genetic Profiling of Breast Cancer throughout the course of disease: from diagnosis, through therapy till recurrence
• Ductal carcinoma in situ (DCIS) subtyping and evolution to invasive ductal carcinoma (IDC): characterizing the invasive potential
• Emergence of mutations in estrogen receptor (ER) under hormonal therapy selection
• BRCA1/2 – related breast cancer: • Mechanisms underlying treatment response & outcome in BRCA-
mutation carriers with triple negative breast cancer • Progesterone-signaling dysregulation in BRCA1 carriers • Whole-Genome profiling of breast cancer: comparing BRCA to non-BRCA
in neoadjuvant treated patients
• Resistance to therapy: Predicting response to therapy in breast cancer by noninvasive assessment of tumor interstitial fluid pressure that forms a barrier to drug delivery
• Tumor microenvironment • Microbiome and Breast Cancer • Immune microenvironment in TNBC
• Breast Tumor Epigenetics
13 IndexBack to
Director of the The Ella Lemelbaum Institute for Immuno-Oncology Sheba Medical Center
The Ella Institute is a center of knowledge and excellence, implementing some of the world's most advanced and unique treatment methodologies for melanoma and skin cancer, operating within the Sheba Medical Center at Tel Hashomer. The services of the Institute are available to patients and their families from the moment the disease is discovered, providing knowledge to patients on the stages of treatment and the procedures they would undergo, and ensuring a suitable and effective treatment for every patient, according to their condition and personal record. The Ella Institute operates in collaboration with leading medical centers in the area of melanoma treatment worldwide, including the National Institute of Health (NIH) in The Unites States of America. The Institute incorporates advanced treatment methodologies with scientific and clinical research which is on going in the advanced research laboratories of the Institute. The Institute offers to patients the most extensive and effective treatment range, including enrollment in advanced clinical trials in the field of melanoma treatment..
The Chaim Sheba Medical Center 14 IndexBack to
Prof. Gal Markel is Head of the Research laboratory at the Ella Institute for the Treatment and Research of Melanoma and Skin Cancer at the Sheba Medical Center
The main objectives of the research laboratory are to define key aspects in the biology of melanoma and translate them into clinical tools of diagnosis and therapy. We therefore focus on robust clinically relevant phenomena, which provide the basis for novel technology development.
In the past decades the increasing knowledge in cellular immunology and tumor-host immune interactions, led to the development of immunotherapy approaches. Immunotherapy, based on Adoptive Cell Transfer (ACT) of ex vivo activated and expanded immune effector cells, has shown promising clinical results in patients with malignant diseases. The Ella Institute offers a clinical study were large amounts of autologous Tumor-Infiltrating Lymphocytes (TIL) are administered to immune-depleted patients with refractory metastatic melanoma. This therapy achieves very high clinical response rates which cannot be accomplished with any other approved technology to date. Today adoptive TIL therapy serves as a platform for a wide range of research projects, which mainly seek the understanding and improvement of immunotherapy for melanoma patients. Taken together, the already established platform of adoptive immunotherapy and the availability of patient samples open the possibility to a very wide range of basic research, projects with clinically relevant applications and scientific collaborations.
Prof. Markel is a Lecturer at the Department of Microbiology and Clinical Immunology at the Sackler Faculty of Medicine, Tel Aviv University. Graduate of the Hadassah Medical School, The Hebrew University of Jerusalem, cum Laude. PhD in Immunology from The Hebrew University of Jerusalem, summa cum Laude. Prof. Markel has published over 30 papers in the scientific literature and is co-inventor of 8 patents
The Chaim Sheba Medical Center 15 IndexBack to
Director of the Cancer Epigenetic Laboratory, and Director of Cancer Ambulatory Day Care Unit, Sheba Medical Center
Our research projects include : • Methylation and polycomb switch - Studying the mechanism of gene silencing
such as DNA methylation and Polycomb (PRC2) mediated H3K27 methylation. • Cancer heterogeneity- It is currently recognized that heterogeneous cellular
subpopulations within tumors strongly impact prognosis, metastatic potential and resistance to therapy; we seek efficient methods to identify and characterize such sub-populations by epigenetic profiling.
• DNA methylation in cancer progression - Analysis of changes in DNA methylation from patients before and after neoadjuvant treatments using novel technics of p-BAT capture
• Developing a platform for single cell RNA-Seq from breast and lung tumors and cells collected from cancerous fluids in order to provide us with highly effective means to dissect tumor heterogeneity.
• ESR1 resistance mutations –Assay of ddPCR to detect resistant point mutation and single amplicon deep sequencing in order to find new resistant mutations of patients treated with different AI’s and Tamoxifen drugs.
The lab of cancer epigenetics at the cancer research center has been studying changes in cancer epigenetics based on most advanced technologies used in cancer research facilities. Our research focuses on the study of the basic mechanisms leading to cancer development as well as developing new techniques to study cancer and course of disease in cancer patients.
The Chaim Sheba Medical Center 16 IndexBack to
Head of MR Research Group & Chief Scientist, The Advanced Technology Center • PhD in Nuclear Physics as part of
collaboration between Tel-Aviv University and Brookhaven National Laboratory (NY).
• Senior Lecturer, Faculty of Medicine, Tel-Aviv Univ.
• Head of MR Research Group & Chief Scientist, The Advanced Technology Center, Sheba Med Center.
• 1 approved and 5 pending patents, 2 patents licensed.
• 58 published papers. • 2 chapters in books. • 1 chapter in Encyclopedia • 142 abstracts presented in
conferences.
Our research performed in collaboration with national & international researchers/industry focuses on:
• Novel MRI-based Treatment Response Assessment Maps (TRAMs) for high resolution differentiation between tumor/treatment-effects. The TRAMs are used routinely (covered by standard medical insurance) in Israel for clinical decision making.
• >400 patients with brain tumors recruited to national international ongoing clinical studies.
• Licensed to Brainlab AG. FDA submission pending. • Seeking collaboration with investigators/industry studying
(pre-clinical/clinical) novel therapeutics where the TRAMs may be applied for accurate determination of response/pseudoresponse/progression patterns.
The Chaim Sheba Medical Center 17 IndexBack to
Our research focuses on: • Extension of the TRAMs technology to lung cancer and CT (to
differentiate tumor/treatment effects), clinical study (IRB recently approved). Seeking investors.
• Electroporation for the treatment of brain tumors , rat studies. We developed a unique brain minimal invasive technique combining tumor tissue destruction with temporary surrounding blood-brain barrier disruption, enabling efficient drug delivery into the infiltrating zone surrounding the brain tumor. Seeking investors and collaboration for combining with immunotherapy.
• MRI-based BBB maps for depiction of subtle BBB disruption in TBI. We developed a novel MRI-based technology for depiction of subtle BBB disruption (pre-clinically /clinically). Mice studies show long term BBB disruption in a TBI model. Seeking collaboration with clinicians where long term TBI patients can be scanned with our protocol. We will calculate the BBB maps depicting subtle BBB disruption to study correlation with cognitive decline/outcome.
The Chaim Sheba Medical Center 18 IndexBack to
Figure: In the TRAMs blue=tumor; red=treatment effects. Example of a GBM patient who failed Treatment #1 and responded to Treatment #2. Standard MRI shows improvement after Treatment #1 while the TRAMs show significant progression (increased blue/tumor volume), consistent with clinical deterioration. Standard MRI shows no changes after Treatment #2 while the TRAMs show significant response (blue/tumorred/treatment-effects), consistent with clinical stabilization.
MRI map MRI map MRI map
baseline Progression under treatment #1 Response to treatment #2
Figure: Example of pseudoprogression. Progression = increase in blue volume. Pseudoprogression = increase in red volume >> increase in blue volume.
• Zach et al, PLoS One, 2012
• Zach et al Neuro Oncology, 2014
• Daniels et al, AJNR, 2016
The Chaim Sheba Medical Center 19 IndexBack to
Improvement of targeted and focal radiation therapy. Chair, Radiation Oncology
Prof Symon is a Clinical Associate Professor in Oncology, Sackler Faculty of Medicine, Tel-Aviv University. Prof. Symon’s research interests include: Prostate cancer treatment outcomes, patient reported outcomes (PROMS) Quality of Life, Image Guided radiation therapy. Focal brachytherapy of prostate cancer using elastic small field of view TRUS MRI fusion using a novel algorithm. Moderate and Extreme Hypo-fractionation and Stereotactic Body Radiation Therapy for prostate cancer. A unique application of Continuous Positive Airway Pressure (CPAP) for immobilization of moving lung tumors for stereotactic Body radiation therapy. CPAP for reduction of cardiac toxicity of breast cancer irradiation. The development of a algorithm for real time multi-leaf collimator tracking of moving tumors using advanced missile tracking technology.
• Elastic TRUS MRI fusion for targeted radiotherapy • Continuous positive airway pressure for improving imaging and RT • Real time MLC tracking • QOL research-hypo-fractionation and SBRT
The Chaim Sheba Medical Center 20 IndexBack to
Senior Physician, Radiation Oncology Medical Director of Radiation Oncology, Lowell General Hospital, Lowell, Mass 1991-2012. Assistant Clinical Professor of Radiation Oncology, New England Medical Center, Tufts University School of Medicine 1993-2013. Dr. Goldstein immigrated to Israel with his wife and 4 children in 2012. He assumed the position of residency director at Sheba Medical Center in 2013 where he has been providing clinical care, teaching residents and conducting retrospective and prospective clinical research. Dr. Goldstein's primary research interest is in the use of CPAP to reduce tumor motion when patients with breast, lung and upper GI tumors receive radiation treatments. Dr. Goldstein's group has presented their findings at numerous scientific meetings and published their initial work in leading radiation oncology publications. A patent application has been submitted for use of CPAP with radiation therapy. In addition, Dr Goldstein has directed resident and student research that incorporates the use of advanced imaging in the fields or prostate, breast, and lung cancer.
Our research focuses on: • Assessing the effects of CPAP on tumor and normal organ position
and motion. • Reducing exposure of the heart to radiation. • Improvements in CT, PET and MRI image quality. • Increasing safety of invasive procedures.
Images show smaller treatment fields when patient uses CPAP. This reduces exposure of the heart, lung and esophagus to radiation. Note reduction of motion artifact.
Without CPAP With CPAP
The Chaim Sheba Medical Center 21 IndexBack to
Our work:
Head, Department of Pathology, Sheba Medical Center. Prof Barshack is Professor of Pathology at the Sackler Faculty of Medicine, Tel-Aviv University and serves as Vice Dean and Head of School of Medicine, Tel- Aviv University Prof. Barshack is Co-Director of the Sheba Tumor Bank and Co-Director of the Molecular Diagnostic Center Precision Medicine Project Digital Pathology Project
• The Department of Pathology in The Sheba Medical Center is dedicated to the diagnosis of pathological findings within tissues and cells.
• The department employs almost 30 medical specialists and residents as well as almost 30 laboratory technician and scientists who hold MA’s and PhD's who lead the different laboratories and play an intricate role in the research projects.
• The department also performs quick exams of frozen sections during surgeries in order to supply answers to the surgeon’s questions that arise during the operation.
• The department conducts autopsies when required. • The department encompasses a laboratory specific for histochemical
staining, a laboratory for immunohistochemical staining which performs In-situ Hybridization as well, a laboratory for PCR, a laboratory for Electron Microscopy, a laboratory for FISH and a Molecular laboratory working on NGS platform. Furthermore, the department includes an advanced system for Digital Pathology including photographing and processing both macroscopic and microscopic constituents.
The Chaim Sheba Medical Center 22 IndexBack to
Our research:
Head of Department of Pathology Co-director of Sheba Tumor Bank Co- director of Molecular Diagnostic Center Precision Medicine Project Digital Pathology Project Vice Dean, Head of School of Medicine, Tel- Aviv University
• The department participates in a large array of research projects with the cooperation of other departments within and outside of the hospital, and internal research of the department itself.
• One of the great accomplishments has been the conceptual implementation of the use of microRNA to aid in the identification of different tissues and the application of this knowledge to identify metastasis of unknown origin. Another area of research in which the department is leading is the development of the technology of tissue microarrays.
• The department is leading the investigation of inflammatory processes and lymphoproliferative tumors according to the production and study of heavy chain B lymphocytes within the tissue. In light of this investigation, the department received a number of important research grants.
• Our new research projects are focused on molecular pathology and precision medicine projects and we also have several new research studies and collaborations based on our interest in digital pathology.
The Chaim Sheba Medical Center 23 IndexBack to
Biologically motivated tissue classifier: Based on a binary decision-tree
Head of Department of Pathology Co-director of Sheba Tumor Bank Co- director of Molecular Diagnostic Center Precision Medicine Project Digital Pathology Project Vice Dean, Head of School of Medicine, Tel- Aviv University
Branched binary tree: Each node of the tree classification proceeds to one of two possible branches grouping together tissues with underlying similarities
Each node is a binary decision between two sets of samples. A structure of decision-tree classifier with 24 nodes and 25 leaves
The Chaim Sheba Medical Center 24 IndexBack to
Research interests and ongoing projects:
• Why and how different Salmonella enterica serovars are differ in host-specificity and clinical outcome • Virulence regulation in Salmonella and its response to environmental signals • Mechanisms of population dynamics and changes in serovars prevalence at the national level • The biology of invasive and persistent Salmonella infections • The role of the Tcf, Ipf and Fae fimbriae in Salmonella pathogenicity • Israeli Adult Invasive Pneumococcal Disease (IAIPD), indirect influence of infants prevnar 13 vaccination • Palestinian-Israeli Collaborative Research – (PICR), MRSA, pneumococci and the effect of pneumococcal vaccination among different populations • Molecular epidemiology of CA MRSA infections in Israel • Staphylococcus aureus carriage from the mother to the infant, longitudinal study • Exploring the role of p53 exonuclease activity in various cellular processes in the cell • Exploration of new antibiotics secreted form novel bacteria • CMV in pregnancy • Epidemiology of resistant bacteria in Sheba medical center (CRE, AMP-c etc) • Invasive Aspergillosis and RSV infections among ICH • Rate and severity of Immune reconstitution inflammatory syndrome (IRIS) among HIV patients receiving antiretroviral therapy (ART) • Clinical and laboratory characteristics of syphilis among HIV 1 positive men having sex with men (MSM) • HIV Viral load escape in the CSF drug resistant mutations • Epidemiology of non tuberculous mycobacteria in Israel
Director, Infectious diseases unit
The Chaim Sheba Medical Center 25 IndexBack to
Director, Liver Diseases Center Prof. Ben-Ari is a Professor of Medicine at the Sackler Faculty of Medicine, Tel Aviv University. In 2012 she established in Sheba the first molecular liver research laboratory. She served as the chairwoman of the Israeli association for the study of liver diseases and is currently the chairwoman of the national council liver committee. She is a member of multiple national and international societies and serves on the editorial board of several leading liver transplantation and Hepatology journals. She is consultant to many biotech companies and is developing a pending patent in the field of liver fibrosis. She is a distinguished invited speaker in many international medical congresses, and has authored more than 155 medical articles.
The molecular liver research laboratory is associated with the Liver Diseases Center. The proximity between both creates a unique and highly successful dynamic relationship where the unsolved clinical needs are translated into research for achieving better solutions. The lab conducts many collaborations with scientists from Israel and from worldwide leading academic and medical institutes.
The Chaim Sheba Medical Center 26 IndexBack to
Our research focuses on: Molecular mechanisms associated with the pathogenesis of
liver fibrosis – an unsolved and important medical issue Utilizing primary hepatocytes and purified hepatic stellate cells
Signal transduction pathways involved in the pathogenesis of
Nonalcoholic Fatty Liver Disease The most globally common liver disease with no medical solution
Utilizing primary fat loaded hepatocytes and purified primary hepatic
stellate cells
The role of the microbiome in liver diseases Detecting the microbiota signature in different liver diseases by
bacterial DNA submitting for 16S rRNA gene sequencing
Discovery of novel bio-markers for the diagnosis and
prognosis of liver diseases of unknown etiology Identification of a specific/unique miRNAs profile that can serve as
a bio-marker
Non-activated
hepatic stellate cells
Activated
hepatic stellate
cells
Lab director: Dr. Michal Safran. [email protected]
The Chaim Sheba Medical Center 27 IndexBack to
Research focus:
Director, IBD Service & Gastro-Immunology Laboratory Gastroenterology Department Shomron Ben-Horin M.D. is an Associate Professor and the Director of the inflammatory bowel disease (IBD) service at Sheba Medical Center, Tel-Aviv University, Israel, where he also heads research at his Gastro-Immunology Laboratory. Prof. Ben-Horin trained in gastroenterology at Sheba Medical Center and was also a Post-Doctoral scientist in human immunology at Columbia University, Presbyterian Hospital in New-York, USA. He has been a distinguished invited speaker in many international medical congresses, has authored more than 110 medical articles and is an Associate Editor of the Journal of Crohn's & Colitis (JCC). He is at present a member of the Scientific Committee of the European Crohn's & Colitis Organization (ECCO). As of 2015 he is also an Adjunct Professor of Medicine at the First Affiliated Hospital of Sun-Yat-Sen University, Guangzhou, China, where he has spent one year of clinical and research work until 2016. Prof. Ben-Horin is consultant to many biomed companies, has initiated medical device development in Gastroenterology and is also the Director of IBD-Passport: An international program to aid travelling IBD patients
• Drug efficacy, IBD immune mechanisms and immunogenicity of biologics • Medical innovations in the field of gastroenterology
Exemplary projects to date: • Devising a novel assay to measure drug & anti-drug antibodies against anti-
TNF drugs (Ben-Horin S, Gut 2011). The assay was later used in multiple studies for improving IBD patients' care (Ben-Horin S, APT 2012, Yanai H, CGH 2015, Ungar B, Gut 2014), and was also chosen as the reference assay for the Bio-Cycle Horizon 2020 European multi-center project and for Abbvie PAILOT study
• Cross-immunogenicity of infliximab biosimilar (Ben-horin S, Gut 2016). Project funded by CELLTRION, and included appearance of Prof. Ben-Horin at the FDA approval Advisory Committee.
• Initiating and leading an international multi-center trial of curcumin as therapy for ulcerative colitis (Lang A, CGH 2015)
• On-going investigator initiated trial of 5ASA in acute severe colitis • Self-propelled capsule endoscope. Project funded by Israel CSO. • Initiation & Chairing of ECCO CONFER – COllaborative Network For Extremely
Rare cases of the European Crohn's & Colitis Organization (ECCO).
The Chaim Sheba Medical Center 28 IndexBack to
Prof. Sarah Ferber is the head of the Endocrine Research Unit at the Sheba Medical Center.
The Endocrine research group develops a novel therapeutic approach, substituting malfunctioning organs with new functional issues created from our own existing organs The group proposes an innovative therapy for diabetes - a new technology for regeneration of functional insulin-producing cells, thus enabling normal glucose regulated insulin secretion, via cell therapy. By using a therapeutic agent (i.e., PDX-1, or additional pancreatic transcription factors in adenovirus-vector) that efficiently converts a sub-population of liver cells into pancreatic islets phenotype and function.
• Identification and characterization of the pancreatic precursor cells in adult human liver
• Unraveling the mechanism behind adult cells reprogramming • Analyzing the differential roles of distinct pancreatic transcription
factors in the developmental redirection process • Analyzing the role of the cellular niche on the maturation of the
transdifferentiated cells • Functional analyses of the newly developed pancreatic tissue both in-
vivo and in-vitro • Analyze the role of adult cells dedifferentiation in the activation of the
alternate pancreatic repertoire in liver
Prof. Sarah Ferber is one of the most recognized world leaders in cell replacement therapy for diabetes. She studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. She completed a post-doctoral fellowship at the Joslin Diabetes Lab at Harvard Medical School. Prof. Sarah Ferber has received the TEVA, LINDNER, RUBIN and WOLFSON awards, in addition to "woman of Achievements" award from the Friends of Sheba in LA-CA-USA.
Our research focuses on:
The Chaim Sheba Medical Center 29 IndexBack to
Research projects in Neurology
Director, Department of Neurology Professor and Director of Department of Neurology, Sheba Medical Center. Robert and Martha Harden Chair in Mental and Neurological Diseases Sackler Faculty of Medicine, Tel Aviv University. Prof. Chapman is head of the department of Neurology at Sheba MC which includes an inpatient service with 40 beds, an active Stroke service and an outpatient clinic with over 30,000 patient visits a year. Prof. Chapman’s research is centered on the role of the coagulation pathway in the electrophysiology of the normal brain and in disease. His lab is involved in drug development based on this pathway in the fields of neuropathy, inflammation and brain tumors. Prof. Chapman has over 170 peer reviewed publications and has received numerous grants.
• Developing new treatment targets in animal models (Prof. Chapman) • Development of novel treatments of movement disorders (Prof. Hassin) • Epidemiology and treatment of acute stroke (Dr. Orion, Prof. Tanne) • Advanced electrophysiology of Epilepsy (Dr Maggio, Dr. Blatt) • Animal and human studies of neuromuscular disease (Dr Dory)
The Chaim Sheba Medical Center 30 IndexBack to
Principal Investigator, The Translational Neurology and Neuro-Electrophysiology Laboratory
Senior Neurologist, Neurophysiologist and Epileptologist, Department of Neurology
Molecular and cellular mechanisms of synaptic plasticity and excitability in health and disease
• Novel molecular strategies for targeting epileptogenesis towards the development of novel therapeutic compounds.
• The role of thrombin and Proteases- Activated Receptor 1 (PAR1) in epileptogenesis.
• Neuro-coagulation: the role of coagulation factors in synaptic plasticity.
• Neuro-inflammation: the role of microglia in health and disease. • Translational Neuroscience: understanding the molecular and cellular
targets of repetitive Transcranial Magnetic Stimulation (rTMS) in synaptic plasticity.
• Clinical research in the field of Epilepsy and Clinical Neurophysiology: use of quantitative EEG as well as translational approaches based on “big data”.
The Chaim Sheba Medical Center 31 IndexBack to
Our research in Multiple Sclerosis focuses on:
Director, Multiple Sclerosis Center Professor of Neurology, Sackler Faculty of Medicine, Tel-Aviv University. Prof. Achiron is Founder and Director of the Multiple Sclerosis Center at the Sheba Medical Center which combines a holistic multidisciplinary approach targeted at the diagnosis, treatment and rehabilitation of patients with multiple sclerosis. Prof. Achiron's research interests are within the fields of neuroimmunology, neuroimaging and cognitive function in multiple sclerosis. She has extensively studied cognitive performance especially in the very early stages of the disease, and was involved in studies evaluating genetic markers associated with the diagnosis of multiple sclerosis, various disease types and prediction of disease activity and treatment responses. Prof. Achiron has published widely, with over 200 publications and has received numerous grants and scientific awards for her research in medicine and neurology.
• Developing new treatment targets • Disease classifiers using Gene expression microarrays • Cognition and cognitive plasticity • Gait & Balance analysis • Virtual reality rehabilitation
The Chaim Sheba Medical Center 32 IndexBack to
Scientific Director, the Center of Advanced Technologies in Rehabilitation (CATR) Dr. Meir Plotnik was trained as a neurophysiologist, and has more than 25 years of experience conducting both animal and human research, on Motor Control and Vestibular Function (balance control). Current positions: Assistant Professor, Tel Aviv University Science Director, Center for Advanced Technologies, Sheba Medical Center Education: Tel Aviv University, Medical School, (M.Sc) Hebrew University, Medical School, (Ph.D) University of Chicago, Chicago, IL, USA (Post-Doc & Faculty)
Our research focuses on: Research domains related to health, neuroscience, and life sciences: • Physiology of gait and vestibular function . • Motor learning, Sensory- motor– cognitive integration in gait and posture. • Pathophysiology of gait and equilibrium disturbances in neurological
conditions . • Mental, psychological and psychiatric interactions with motor performance. Research topics related to Information and Communication Technologies (ICT) including Physics, Computation and Engineering: • Complexity in physiological networks – for short and long term physiological
processes, based on signal processing data obtained from physiological sensors.
• Development of miniaturized wearable devices for diagnosis and treatment. • Technologically based diagnostic, treatment, rehabilitation and tele –
rehabilitation tools. • Research on Virtual reality technologies – human- machine interface.
The Chaim Sheba Medical Center 33 IndexBack to
Our research in neurological rehabilitation focuses on: • Developing new rehabilitation techniques for people with
acute, sub-acute and chronic severe neurological conditions such as spinal cord and brain trauma, stroke, MS and Parkinson’s disease
• Developing new (high and low cost) technologies for improving function and inducing CNS plasticity in people with chronic disabilities due to neurological conditions such as :
• Brain – computer interfaces • Motor and speech tele rehabilitation • Transcutaneous cortical and spinal cord electrical
stimulation
• Tablets and video games • Central neuropathic pain
Director, Department of Neurological Rehabilitation and The National Spinal Cord Injury Rehabilitation Unit Senior lecturer in Rehabilitation, Sackler Faculty of Medicine, Tel-Aviv University. Prof. Zeilig has been Director of the Department of Neurological Rehabilitation at the Sheba Medical Center, Tel Hashomer since 1999. He was certified as a specialist in PM&R in 1990, at the Tel Aviv University, Israel. He has continued on the staff since that time, He undertook a Critical Care Neurotrauma and Neurorehabilitation fellowship at the University of Maryland Medical Center, Baltimore, USA. The results of his research have been published in many papers in peer-reviewed international medical journals or presented in international conferences. Prof. Zeilig is a member of the Editorial Boards in scientific journals. Prof. Zeilig is the head of the department of PM&R at the Sackler School of Medicine, Tel Aviv University.
The Chaim Sheba Medical Center 34 IndexBack to
Main research focuses:
Head, Electrophysiology Clinic Goldschleger Eye Institute, Sheba Medical Center Director of Electrophysiology Service, Goldschleger Eye Research Institute, and Head of the Retinal Research Laboratory, Goldschleger Eye Research Institute, Sheba Medical Center. Senior Lecturer, Sackler Faculty of Medicine, Tel Aviv University. Medical Advisor Accutome, Halma, USA. Founder and Medical Director, Epitech-Mag Inc. Founder and Medical Director, EVERADS Inc. Chair of Ethical & Regulation Committee, ARVO.
• Facing unmet needs, I lead multidisciplinary clinical trials, basic science and translational medicine aimed at development of novel treatments and diagnostic tools for retinal & brain degeneration . Specifically we study:
• Development of novel treatments for neuroretinal degeneration: stem cell based therapies , synthetic and natural 9-cis beta carotene therapy
• The immune system in retinitis pigmentosa : the role of microglia activation in disease progression.
• Drug delivery systems to the posterior segment : novel injection devices and nanotherapies.
• Objective Perimetry: an innovative chromatic multifocal pupillometry : non invasive diagnostic tool for retinal degeneration and optic nerve diseases (e.g. glaucoma, optic neuritis).
• The eye as a window to the brain – using retinal structure & function measurements as novel early & objective biomarkers for brain neurodegeneration diseases (e.g. Alzheimer’s disease and multiple sclerosis), brain injuries and brain tumors.
• Repetitive magnetic stimulation for treatment of dry eye.
• Deep learning for identification retinal biomarkers.
The Chaim Sheba Medical Center 35 IndexBack to
Our work focuses on:
Director, Pediatric Nephrology Unit & the Pediatric Stem Cell Research Institute, Edmond and Lily Safra Children’s Hospital Prof. Benjamin Dekel is Associate Professor of Pediatrics, Human Molecular Genetics and Biochemistry, Tel Aviv University. President, Israel Stem Cell Society. Member, American Society of Clinical Investigation (ASCI). Member, Society of Pediatric Research (APS/SPR) Visiting Professor, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University The Youdim Family Prize Winner for Excellence in Cancer Research Founder, KidneyCure
• Identification, isolation and expansion of novel tissue-resident
human stem cells.
• Application of tissue-resident stem cells in pre-clinical models of
chronic kidney disease.
• Development of methods for 3D growth of human tissues.
• Utilization of 3D human spheroids for kidney regeneration.
• Direct Reprogramming of differentiated cells to tissue stem cells.
• Identification, isolation and expansion of novel human cancer stem
cells using PDX models.
• Discovery of novel cancer stem cell antigens for targeted therapy.
• Application of targeted therapy aimed at eradicating human cancer
stem cells in PDX models.
The Chaim Sheba Medical Center 36 IndexBack to
Director of Research and Development in Edmond and Lily Safra Children Hospital and the Section of Functional Genomics and Childhood leukemia and Cancer research Prof Izraeli is a Professor and Chair of Hematological Malignancies at the Sackler Faculty of Medicine, Tel - Aviv University. His research focuses on the molecular pathogenesis of childhood leukemia. He has authored over 150 peer reviewed publications in the leading biomedical journals. He is Co-Chair of the Israeli National Study of childhood leukemia. He has extensive international collaborations and educational activities. He is an elected Board member and the head of the scientific committee of the European Hematology Association. He won numerous international prizes including the Presidential Award of the British Society of Hematology and the Italian President Honorary Knighthood.
Cancer is the leading cause of death from disease in children. Leukemias and hematopoietic malignancies are the most common types of cancer in children. Our ultimate goal is to cure all children with leukemia and cancer with personalized adjustment of therapy to the severity of the disease and to the molecular genetic abnormalities in the cancer cells. Some of Prof Izraeli major discoveries: • The discovery of high risk childhood leukemias driven by JAK-STAT signaling. This discovery has
lead to clinical trials with JAK inhibitors for childhood and adult ALL. • The discovery of ERG as a major leukemia oncogene • The discovery of a novel immunological mechanism of central nervous system leukemia, a
major problem of childhood leukemia • The discovery of STIL as essential for centriolar replication and as a target for epithelial cancer
therapy including ovarian, colon, lung, breast and brain cancer
The Chaim Sheba Medical Center 37 IndexBack to
Incorporation of new treatment modalities: Research areas:
Director, Division of Pediatric Hemato-Oncology and Bone Marrow Transplantation, The Edmond & Lily Safra Children’s Hospital Prof. Amos Toren is Director of the Division of Pediatric Hemato-Oncology and BMT at the Sheba Medical Center, Tel Hashomer Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He is a Professor of Hematology, Sackler Faculty of Medicine Tel-Aviv University and served as the Head of this division for 2 terms. He has a PhD in genetics and a Master of Health Administration (MHA) at the Recanati Business School, Tel-Aviv.
• Targeted therapies aimed at new targets identified by in-house analysis of genetic panels studying the DNA of pediatric cancer patients
• Immunotherapy with new bispecific antibodies • Cytokine induced killer cells against pediatric tumors • Incorporation of checkpoint inhibitors • Study of T- CARs for patients with relapsed/resistant CD19 expressing leukemias
and lymphomas. This innovative treatment performed only in a few centers in the USA was successfully given to 5 patients
• Pediatric brain tumors and neuroblastoma studies in the lab including pathogenesis, innovative therapies, discovery of new molecular aberrations, new biomarkers, new therapeutics target the effect of new drugs on cell lines, primary cells and xenografts, studying the influence of changes in the levels of non-coding RNA's (mirs and link-RNA) on the tumor
• Improvement of the activity of cytokine induced killer cells stemming from alfa/beta depleted T cells left over after haploidentical transplantations
• Studying the effects of phytocannabinoids, synthetic cannabinoids and endocannabinoid like substances on pediatric glioblastomas and neuroblastoma.
The Chaim Sheba Medical Center 38 IndexBack to
Director of Pediatric Department A, and the Pediatric Immunology Services, Jeffrey Modell Foundation Center, The Edmond & Lily Safra Children’s Hospital Associate Professor of Pediatrics, Sackler School of Medicine, Tel-Aviv University. PhD, Tel Aviv University . Director Pediatric Department A. Head, the Jeffrey Model Center for Excellence in Primary Immunodeficiency). Chairman of the Israeli Primary Immunodeficiency society. Head, the National Laboratory for Diagnosis of SCID - the Israeli newborn screening program. Participated in a famous documentary film called "Precious Life”. Published more than 100 peer review original studies, case reports and review articles. Over the years, established close collaborations with the Palestinian Authorities and Doctors.
Our research focuses on: • Primary immunodeficiencies-novel diseases • Newborn screening for immunodeficiency • Fetal immunity • Next generation sequencing for T and B cell receptor repertoires
•The pediatric immunology clinic and laboratory are dedicated to the diagnostic evaluation, treatment, monitoring and research of patients with disorders of the immune system, including congenital immunodeficiencies and autoimmune diseases. •We lead the field of newborn screening for severe immunodeficiency in Israel and are the national laboratory for validating results obtained from this program. •We are acknowledged as a "Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency" (www.jmfworld.org) –the "gold standard" benchmark for excellence in this field. • Our in-house laboratory provides the most advanced immunological and molecular assays that are used world-wide to assess immune function. The main focus of our lab is to investigate T and B cell development and repertoire productions in health and disease including the development of the immune system in fetal life., • Using the CRISPR-Cas9 genome editing platform, we are modeling relevant primary immunodeficiency-causing genes, such as RAG1/2, DCLRE1C (artemis) and ATM in wild type human lymphocytic cell-lines, and are using this 'bed to bench and back' approach to correct these mutated genes as a strategy to develop innovative curative gene correction therapy in patients' cells. •Many of our studies already matured into publications in highly esteemed scientific and medical journals including the New England Journal of Medicine, Journal of Experimental Medicine, Science Translational medicine, Journal of Allergy and Clinical immunology.
The Chaim Sheba Medical Center 39 IndexBack to
• Cardiac microRNAs as early biomarkers for the post-operative course of
children with Congenital Heart Disease
• MicroRNAs as biomarkers in neonates with Hypoxic Ischemic Encephalopathy
• MicroRNAs as biomarkers of disease in children with Fever Without an apparent
Source
The Inflammatory Response to Life threatening Disease:
The Hypoxic Response in Critical Care Illness:
• The role of STAT3β in regulating genes upon hypoxia
• Cytokines following repair of congenital heart disease
• Adipokines in critical care illness
Novel Biomarkers in Critical Care
We seek collaboration with investigators/industry studying novel
biomarkers for the rapid and precise determination of disease and therapy.
We investigate scientific issues that arise in the unique and complex field of Pediatric Intensive Care and find solutions to questions raised by clinicians using basic science methodologies.
Our research focuses on:
Director, Department & Laboratory of Pediatric Intensive Care Professor Gidi Paret is Director of the Dept. of Pediatric Intensive Care and the Pediatric Critical Care Laboratory of Molecular Biology Research at the Sheba Medical Center.
Prof. Paret is Professor of Pediatrics at the Sackler Faculty of Medicine, Tel Aviv University, and has authored more than 150 peer reviewed scientific publications, review articles, and book chapters. He is a member of the editorial board of the Pediatric Critical Care Medicine Journal. Former Chairman of the Israeli Society of Pediatric Critical Care Currently serves as the Chairman of the Scientific Council of the Israeli Medical Association.
The Chaim Sheba Medical Center 40 IndexBack to
Director of the Cardiovascular Research Institute Prof. Leor is a Professor of Cardiology, Sackler Faculty of Medicine, Tel-Aviv University. Director of the Cardiovascular Research Institute, and the Center of Regenerative Medicine at the Sheba Medical Center. Leor is a world-renowned leader and pioneer in the development of novel cardiovascular regenerative therapies. He is a co-inventor of breakthrough injectable biomaterial to treat heart attacks, which was licensed by a major US drug company.
Our research focuses on:
• Targeting and modulating macrophages • Myocardial regeneration • Cardiovascular ageing and longevity • Targeting inflammation in atherosclerosis • Injectable Tissue Engineering
leorlab.wixsite.com/leor
The Chaim Sheba Medical Center 41 IndexBack to
Director, Department of Cardiology and Israeli association for cardiovascular trials Prof Ilan Goldenberg is Professor at the Sackler Faculty of Medicine,Tel Aviv University and the University of Rochester. In 2004 he joined the Heart Research Follow-up Program at the URMC and over 7 years was involved in clinical research that included genotype-specific risk stratification in patients with the long QT syndrome, genetic risk for early myocardial infarction, indications for therapy with implantable devices, including the implantable cardioverter defibrillator and cardiac resybchronization therapy, and studies that involve the wearable cardioverter defibrillator. He has published more than 400 original articles, book chapters, and reviews.
• Epidemiology and prevention • Risk stratification for sudden cardiac death • Inherited arrhythmias • Implantable devices for the prevention
sudden death and heart failure • Heart failure: Treatment and prevention
Our research focuses on:
The Chaim Sheba Medical Center 42 IndexBack to
Our research focuses on:
Director, Division of Cardiology Associate Professor of Cardiology at the Sackler Faculty of Medicine, Tel Aviv University. Director, Division of Cardiology, Sheba Medical Center Over 20 years of experience in interventional and clinical cardiology. Completed a Fellowship in Interventional Cardiology at St. Michael’s Hospital, Toronto, Canada
• Trans-catheter Aortic Valve Implantation (TAVI)
• Pulmonary hypertension and hemodynamic assessment
• First-In-Human studies of novel cardiovascular devices: mitral annuloplasty ring, vascular closure devices
The Chaim Sheba Medical Center 43 IndexBack to
Our research focuses on:
Director, Catheter Laboratory Service Associate Professor of Cardiology, the Sackler Faculty of Medicine, Tel Aviv University. An expert in coronary and structural Interventional Cardiology, and has been studying basic and clinical cardiology for over 20 years. Fellowship in Interventional Cardiology at the Cleveland Clinic – MedStar Washington Hospital Center in Washington DC. He also graduated a Fellowship at the Cardiovascular Intervention Program at NHLBI, NIH, Bethesda, MD.
• Clinical research in assessment of patient clinical outcomes after TAVR (Transcatheter aortic valve replacement)
• First-In-Human studies of novel cardiovascular devices: mitral annuloplasty ring, vascular closure devices
• Basic research: Real-time MRI-guided percutaneous cardiovascular interventions.
The Chaim Sheba Medical Center 44 IndexBack to
Director of Arrhythmia Center Trained in cardiology at the Sheba Medical Center then at the Mayo Clinic for 2 years in pacing and electrophysiology . Director of electrophysiology since 2002 and of the arrhythmia center since its establishment . Clinical Professor of Cardiology Sackler Faculty of Medicine, Tel-Aviv University and the author of > 150 scientific papers . Serving now as the president of Israel Heart Society and chair of the scientific program committee of the European Heart Rhythm Association
• We are the largest Ep / pacing group in the country performing all kinds of procedures. We are leaders in complex device procedures, complex ablations, extractions and were the first to introduce new technologies into the country.
• Over the years we were involved in nearly 50 multicenter clinical studies mainly in the device area, including studies initiated by ourselves.
• Our research laboratory is involved in the research of genetic arrhythmic syndromes and uses molecular genetic techniques, patch clamping and wedge preparations for translational research.
• We have direct approach to many databases and registry data that are run out of the ACTI research institute in collaboration with ourselves. We were involved with a lot of research projects based on the Israeli ICD registry.
• Our physicians are extensively involved in collaboration with the industry including animal lab projects as well as early stage and FIM studies in the field of device, extraction and ablations.
• We have been involved in fellow training from abroad for many years with our alumni spread all over the world.
• We have extensive collaboration with overseas groups including Mayo Clinic as well as prominent groups in MGH and Brigham &Women in Boston MA.
The Chaim Sheba Medical Center 45 IndexBack to
Our research focuses on:
Director of the Cardiac Rehabilitation and Prevention Institute Chair of the Israeli Working Group on Cardiac Rehabilitation Over 50 research paper in the field of rehabilitation \ prevention and risk prediction.
• Exercise training in Heart Failure and specifically in subjects with cardiomyopathy or pulmonary hypertension
• Prevention of readmission through exercise • Telemedicine in cardiac rehabilitation and use of wearable
devices • Primary and secondary prevention of coronary disease
Active Projects: • Multicenter registry exercise in heart failure
• Impact of novel hypoglycemic meds on exercise capacity • Exercise in hypertrophic cardiomyopathy • Tele-rehab pilot study • Wearable devices in cardiac rehab • Association between exercise capacity improvement and
hospitalizations
The Chaim Sheba Medical Center 46 IndexBack to
Our research in Lipids and Atherosclerosis focuses on:
Head of the Vascular Biology Research Unit at The Bert W. Strassburger Lipid Center, the Talpiot Sheba Medical Leadership Program Academic Degree: Senior Lecturer in Medicine, Sackler School of Medicine, Tel-Aviv University. Dr. Kamari is a physician scientist who combines clinical work using a holistic approach for prevention and treatment of atherosclerosis in high risk patients, with basic research. Dr. Kamari's research interests are within the fields of metabolic inflammation which contributes to the derangements of fat accumulation in atherosclerosis, fatty liver disease and diabetes. He has extensively studied the role of inflammatory cytokines and specifically IL-1 in early and advanced stages of atherosclerosis and fatty liver disease. He also discovered an unexpected role of IL-1 in determining ovarian lifespan and fertility. Dr. Kamari has published over 35 publications to his name in important scientific journals including PNAS and Journal of Hepatology, and has received numerous grants and scientific awards for his research work in
cytokine biology.
• Tissue specific role of cytokines in atherosclerosis using transgenic mice
• Expression pattern of inflammatory genes in Macrophages
• Endoplasmic Reticulum stress in metabolic inflammation
• Developing new treatment targets • The role of the ubiquitin like protein FAT10 in
atherosclerosis and fatty liver disease
The Chaim Sheba Medical Center 47 IndexBack to
Research focuses on: Director,
Heart Transplantation Unit Professor of Surgery Sackler Faculty of Medicine Tel Aviv University
President, Israel Transplantation Society
Chairman, Heart and Lung Transplantation Committee, Israel National Transplant Center
Board of Directors, Declaration of Istanbul Custodian Group International & Inter-society Coordination Committee, International Society of Heart and Lung Transplantation
• Novel mechanical circulatory support technologies
• Improving outcomes of heart transplantation
• Augmenting organ donations
The Chaim Sheba Medical Center 48 IndexBack to
Our research in atherosclerosis
focuses on:
The Effect of 9-cis and all-trans beta-carotene (of the alga Dunaliella)
and their cleavage products on atherosclerosis development.
• The Effect of Dunaliella carotenoids on the activation of the nuclear receptor RXR.
• The effect of 9-cis β-carotene on reverse cholesterol transport (RCT) in mouse models and in isolated macrophages.
• The effect of 9-cis beta-carotene rich powder of the alga Dunaliella on Alzheimer’s disease in transgenic mice.
Researcher, The Bert W. Strassburger Research Center The current research interest of Dr. Shaish is in the prevention and treatment of atherosclerosis, with emphasis on the use of 9-cis beta-carotene from the unicellular alga Dunaliella, as a therapeutic means in this disease and related diseases. The alga is the best known source of beta-carotene in nature and is cultivated by N.B.T in Eilat city, Israel. His research is supported by Nikken Sohonsha, Japan. Dr. Shaish has published widely, with over 100 publications to his name.
The Chaim Sheba Medical Center 49 IndexBack to
